BR0215395A - Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue - Google Patents
Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangueInfo
- Publication number
- BR0215395A BR0215395A BR0215395-5A BR0215395A BR0215395A BR 0215395 A BR0215395 A BR 0215395A BR 0215395 A BR0215395 A BR 0215395A BR 0215395 A BR0215395 A BR 0215395A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- prophylaxis
- diseases
- compound
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- ACMYQAYEINJXQI-UHFFFAOYSA-N pyrimido[5,4-e][1,2,4]triazine-5,7-diamine Chemical class N1=CN=NC2=NC(N)=NC(N)=C21 ACMYQAYEINJXQI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34393701P | 2001-12-27 | 2001-12-27 | |
| US39911002P | 2002-07-26 | 2002-07-26 | |
| PCT/EP2002/014771 WO2003055883A1 (en) | 2001-12-27 | 2002-12-27 | Pyrimidotriazines as phosphatase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0215395A true BR0215395A (pt) | 2004-12-07 |
Family
ID=26993696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0215395-5A BR0215395A (pt) | 2001-12-27 | 2002-12-27 | Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6642381B2 (enExample) |
| EP (1) | EP1467996B1 (enExample) |
| JP (1) | JP4188839B2 (enExample) |
| KR (1) | KR100601769B1 (enExample) |
| CN (1) | CN100402530C (enExample) |
| AT (1) | ATE311388T1 (enExample) |
| AU (1) | AU2002367190B2 (enExample) |
| BR (1) | BR0215395A (enExample) |
| CA (1) | CA2471265C (enExample) |
| DE (1) | DE60207759T2 (enExample) |
| ES (1) | ES2252554T3 (enExample) |
| JO (1) | JO2242B1 (enExample) |
| MX (1) | MXPA04006266A (enExample) |
| PA (1) | PA8562901A1 (enExample) |
| PE (1) | PE20030896A1 (enExample) |
| PL (1) | PL371180A1 (enExample) |
| TW (1) | TW200306313A (enExample) |
| UY (1) | UY27606A1 (enExample) |
| WO (1) | WO2003055883A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002342859B2 (en) * | 2001-10-30 | 2007-07-26 | Merck Serono Sa | Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPS) |
| DE60327097D1 (de) | 2002-11-18 | 2009-05-20 | Hoffmann La Roche | Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren |
| JP2006518738A (ja) * | 2003-02-12 | 2006-08-17 | トランス テック ファーマ，インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| WO2004071448A2 (en) * | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| CA2551909C (en) * | 2004-02-12 | 2011-10-11 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7723369B2 (en) * | 2006-01-30 | 2010-05-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010083645A1 (en) * | 2009-01-21 | 2010-07-29 | Shanghai Targetdrug Co., Ltd | PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US9486433B2 (en) | 2012-10-12 | 2016-11-08 | Mochida Pharmaceuticals Co. Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| SG11201507288UA (en) | 2013-03-15 | 2015-10-29 | Mochida Pharm Co Ltd | Compositions and methods for treating non-alcoholic steatohepatitis |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP3004138B1 (en) | 2013-06-05 | 2024-03-13 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194410B1 (en) * | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| GB0022079D0 (en) | 2000-09-08 | 2000-10-25 | Inst Of Molecul & Cell Biology | Novel protein tyrosine phosphatase inhibitor |
-
2002
- 2002-12-10 US US10/315,769 patent/US6642381B2/en not_active Expired - Fee Related
- 2002-12-24 PA PA20028562901A patent/PA8562901A1/es unknown
- 2002-12-25 TW TW091137302A patent/TW200306313A/zh unknown
- 2002-12-26 JO JO2002137A patent/JO2242B1/en active
- 2002-12-26 UY UY27606A patent/UY27606A1/es not_active Application Discontinuation
- 2002-12-27 EP EP02805774A patent/EP1467996B1/en not_active Expired - Lifetime
- 2002-12-27 DE DE60207759T patent/DE60207759T2/de not_active Expired - Lifetime
- 2002-12-27 JP JP2003556413A patent/JP4188839B2/ja not_active Expired - Fee Related
- 2002-12-27 ES ES02805774T patent/ES2252554T3/es not_active Expired - Lifetime
- 2002-12-27 WO PCT/EP2002/014771 patent/WO2003055883A1/en not_active Ceased
- 2002-12-27 BR BR0215395-5A patent/BR0215395A/pt not_active IP Right Cessation
- 2002-12-27 AU AU2002367190A patent/AU2002367190B2/en not_active Ceased
- 2002-12-27 PL PL02371180A patent/PL371180A1/xx not_active Application Discontinuation
- 2002-12-27 CA CA2471265A patent/CA2471265C/en not_active Expired - Fee Related
- 2002-12-27 KR KR1020047010017A patent/KR100601769B1/ko not_active Expired - Fee Related
- 2002-12-27 MX MXPA04006266A patent/MXPA04006266A/es active IP Right Grant
- 2002-12-27 AT AT02805774T patent/ATE311388T1/de not_active IP Right Cessation
- 2002-12-27 CN CNB028264223A patent/CN100402530C/zh not_active Expired - Fee Related
-
2003
- 2003-01-06 PE PE2003000022A patent/PE20030896A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003055883A1 (en) | 2003-07-10 |
| CN1610683A (zh) | 2005-04-27 |
| PE20030896A1 (es) | 2003-11-05 |
| US6642381B2 (en) | 2003-11-04 |
| AU2002367190B2 (en) | 2006-10-05 |
| ATE311388T1 (de) | 2005-12-15 |
| ES2252554T3 (es) | 2006-05-16 |
| JP2005517677A (ja) | 2005-06-16 |
| CA2471265A1 (en) | 2003-07-10 |
| EP1467996B1 (en) | 2005-11-30 |
| CA2471265C (en) | 2010-02-09 |
| EP1467996A1 (en) | 2004-10-20 |
| KR100601769B1 (ko) | 2006-07-19 |
| DE60207759T2 (de) | 2006-08-03 |
| JO2242B1 (en) | 2004-10-07 |
| CN100402530C (zh) | 2008-07-16 |
| KR20040068981A (ko) | 2004-08-02 |
| MXPA04006266A (es) | 2004-09-27 |
| PL371180A1 (en) | 2005-06-13 |
| US20030153756A1 (en) | 2003-08-14 |
| TW200306313A (en) | 2003-11-16 |
| DE60207759D1 (de) | 2006-01-05 |
| AU2002367190A1 (en) | 2003-07-15 |
| PA8562901A1 (es) | 2003-07-28 |
| JP4188839B2 (ja) | 2008-12-03 |
| UY27606A1 (es) | 2003-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0215395A (pt) | Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| BR0209129A (pt) | Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos | |
| BRPI0410081A (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto | |
| BR0317358A (pt) | Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BR0310092A (pt) | Combinação de compostos orgânicos | |
| BR0213540A (pt) | Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos | |
| BRPI9917739B8 (pt) | composto intermediário na preparação de inibidores de cox-2 | |
| TNSN99106A1 (fr) | Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| BR0211118A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
| BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
| BR9713465A (pt) | Inibidores metalotprotease de amina cìclica sibstituìda | |
| BR0211122A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
| EP1592689A4 (en) | 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
| EP1589969A4 (en) | 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
| BR0316502A (pt) | Compostos quìmicos | |
| BR0206935A (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto | |
| BR0209127A (pt) | compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
| BR0208887A (pt) | Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas i de mglur2 | |
| DK1268498T3 (da) | Kardioprotektive phosphater | |
| BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
| BR0209128A (pt) | Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| ES8609312A1 (es) | Procedimiento para la preparacion de silibinina exenta de isosilibina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |